The Food and Drug Administration (FDA) in the USA has granted Orphan Drug Designation to ISA Pharmaceuticals BV, an immunotherapy company, for its lead product ISA101b, intended for the treatment of Human Papilloma Virus type 16 (HPV16)-positive cervical cancer, it was reported on Wednesday.
The therapeutic is a clinical-stage immunotherapy targeting HPV16-induced diseases and induces specific immune responses to the oncogenic E6 and E7 proteins of HPV16 and is based on ISA Pharmaceuticals BV's proprietary Synthetic Long Peptide technology. It is designed to mount a highly specific, broad and durable, T-cell mediated attack by the immune system on tumours that are positive for human papilloma virus type 16
ISA101 has indicated that it is an effective monotherapy in patients with early stage, HPV16 positive, premalignant neoplasias.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval